🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

51 results for “LEXICON” Clear

  1. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  3. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  4. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Obstructive Cardiomyopathy, Hypertrophic

    phase 3 small molecule active

    1 trial

  5. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  6. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  7. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  8. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Heart Failure

    phase 3 small molecule terminated

    2 trials

  9. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  10. Sotagliflozin (SAR439954)

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  11. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  12. Telotristat etiprate

    LEXICON PHARMACEUTICALS, INC.

    Carcinoid Syndrome

    phase 3 small molecule completed

    5 trials

  13. 250 mg LX1033 tablets

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  14. 75 mg LX4211

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  15. Gemcitabine

    LEXICON PHARMACEUTICALS, INC.

    Locally Advanced Unresectable Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  16. LX1031 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  17. LX3305 low dose

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  18. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. LX6171 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  20. LX7101 (0.125%)

    LEXICON PHARMACEUTICALS, INC.

    Primary Open-angle Glaucoma

    phase 2 small molecule completed

    1 trial

  21. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  22. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  23. Placebo (blinded)

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  24. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes

    phase 2 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources